Author

M. J. DeBell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

T. S. Scanlan· 2 shared B. A. Napier· 1 shared B. Emery· 1 shared D. Bourdette· 1 shared E. Calkins· 1 shared E. Pocius· 1 shared G. Marracci· 1 shared H. Miller· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

T. S. Scanlan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TREM2 is thyroid hormone regulated making the TREM2 pathway druggable with ligands for thyroid hormone receptor

S. J. Ferrara, P. Chaudhary, M. J. DeBell, G. Marracci, H. Miller, E. Calkins, E. Pocius, B. A. Napier, B. Emery, D. Bourdette, T. S. Scanlan

This study shows TREM2 is regulated by thyroid hormone and demonstrates that thyroid hormone agonists can modulate TREM2 pathway activity in myeloid cells, offering a potential therapeutic strategy for diseases involving TREM2.

bioRxiv · Jan 25, 2021Immunology

Pharmacological complementation remedies an inborn error of lipid metabolism

M. D. Hartley, M. D. Shokat, M. J. DeBell, T. Banerji, L. L. Kirkemo, T. S. Scanlan

This study tests two pharmacological strategies to enhance sobetirome's efficacy in lowering VLCFAs in X-ALD mice, finding that Sob-AM2 improves CNS VLCFA reduction but is limited by turnover kinetics.

bioRxiv · Jan 31, 2020Pharmacology & Toxicology